DOCSLIB.ORG

Drug Effects Viewed from a Signal Transduction Network Perspective

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

SUPPORTING INFORMATION SECTION Drug Effects Viewed From a Signal Transduction Network Perspective Anton F. Fliri,†,‡ William T. Loging§ and Robert A. Volkmann*,†,‡ †Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. ‡SystaMedic Inc.,1084 Shennecossett Road, Groton, CT 06340, USA. §Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA. TABLE OF CONTENTS 1320 Medicines Used in This Investigation……………………………………………S2 1179 Proteins (Accession Numbers) used for generating the co-investigation frequency spectra………………………………………………………………………………….S33 1082 COSTART terms…………………………………………………………………S60 Proteins (Accession Numbers) in network fragments I-IX…………………………….S83 Supplementary Tables 1& 2……………………………………………………………S99 Network Fragments I-IX………………………………………………………………S100 S1 Supplementary Figure 1: 1320 medicines COMP_NAME Desoximetasone Betamethasone Fludrocortisone Halometasone monohydrate Betamethasone-21-Valerate Fludrocortisone Acetate Flumethasone Pivalate Paramethasone Acetate 6Beta-Hydroxycortisol Hydrocortisone Prednisolone Prednisone Meprednisone Beclomethasone Dipropionate Clobetasol Propionate Clocortolone Pivalate Fluticasone Propionate Mometasone Furoate Loteprednol etabonate Fluocinonide Halcinonide Fluocinolone Acetonide Flurandrenolide Triamcinolone Acetonide 1,3,5(10)-Estratrien-3,17Beta-Diol-6-One 4-Hydroxyestrone 2-Hydroxyestradiol 2-Hydroxyestriol 4-Hydroxyestradiol Estriol 1,3,5(10)-Estratrien-2,3-Diol-17-One 2-Methyl Ether 2-Methoxyestradiol Beta-Estradiol 3-Methyl Ether Mestranol Ethinyl Estradiol 17Beta-Estradiol 17-Hemisuccinate Estradiol Cypionate Estradiol Valerate Equilenin Podocarpic Acid Allopregnanolone S2 Androstanolone Dehydrocholic Acid Ursodiol Terpin Hydrate Alprostadil Dinoprostone Misoprostol Allethrin Triacetin Latanoprost Loxoprofene Quinic Acid Succinic Anhydride Budesonide Digitoxin Mupirocin Mycophenolate Mofetil HCl Lovastatin Simvastatin Pravastatin Artemether Artesunate PNU-0091638 Piperonyl Butoxide SC-41930 SC-53228 11-Beta,17-Alpha-Dihydroxypregn-4-Ene-3,20-Dione 17Alpha-Hydroxypregnenolone 4-Androsten-4-Ol-3,17-Dione 17Alpha-Hydroxyprogesterone Medroxyprogesterone Medrysone Enoxolone Oleanolic Acid Desogestrel Gestrinone Gestodene Norgestrel 5-Cholesten-3Beta-Ol-7-One Calcifediol 19-Hydroxyandrost-4-Ene-3,17-Dione Uvaol 17 Alpha-Dihydroequilin S3 Equilin Norethindrone Norethynodrel Testosterone Tibolone Exemestane Dydrogesterone Progesterone Canrenone Spironolactone Chlormadinone Acetate Ethynodiol Diacetate Norethisterone Acetate Melengestrol Acetate Medroxyprogesterone Acetate Megestrol Acetate Nomegestrol Acetate Desoxycorticosterone Pivalate Hydroxyprogesterone Caproate Testosterone Decanoate All-Trans-Retinol Phytonadione Ubidecarenone Clofibrate Ciprofibrate Bromopropylate Fenofibrate Deltamethrin Cyfluthrin Lambda-Cyhalothrin Fenpropathrin Fenvalerate 3,4 Dichlorophenol Chloroxylenol Haloprogin Bis(2-Hydroxy-5-Chlorophenyl) Bithionol Dichlorophen Hexachlorophene Diflunisal Flurbiprofen 2-Amino-5-chlorobenzophenone Bupropion HCl S4 Dicofol Plifenate Lindane Mitotane Acemetacin Indomethacin Cerivastatin Fluvastatin Montelukast Sodium 1,5-Isoquinolinediol 5,7-Dichlorokynurenic Acid Fenarimol Metyrapone FPL 64176 Bisacodyl Papaverine HCl RG-13022 Ethacrynic Acid Butylparaben Ethylparaben Gemfibrozil Octyl Salicylate Ethyl 2-Cyano-3,3-Diphenylacrylate Dienestrol Diethylstilbestrol Chlorotrianisene Dienestrol Diacetate Phenothrin Enterodiol Monobenzone Nabumetone Citrinin Dehydroacetic Acid Dithianon 1,4-Benzoquinone Menadione Phenindione Benzoyl Peroxide Ketoprofen Mandelic Acid Pyromellitic Acid Ibuprofen Niacin S5 2-Tert-Butyl-4-Hydroxyanisole 3-tert-Butyl-4-hydroxyanisole Guaiacol Propofol Probucol 2,2'-Dihydroxy-4,4'-Dimethoxybenzophenone Oxybenzone Erbstatin Analog Fenoprofen Sodium Methylparaben Naproxen Aspirin Diacerein Triflusal Aloe-Emodin Emodin Butein Isoliquiritigenin Phloretin Resorcinol Salicylic Acid Aurintricarboxylic Acid Salsalate Trisalicylic Acid Aurothioglucose Amygdalin Trihydrate Arbutin Guaifenesin Aloin Mangiferin Diosmin Rutin Aflatoxin B1 Aflatoxin G1 Etoposide Teniposide PD-0156707-0015 Podophyllotoxin Cromolyn Sodium Dicumarol Coumestrol Methoxsalen Gallocatechin Gallate, (-)- S6 Gossypetin Kaempferol Hematein PCO 400 O-Cresolphthalein Phenolphthalein Bromadiolon Coumachlor Warfarin Phenprocoumon Amifostine CGP 35348 Alendronate Sodium Pamidronate Ibandronate sodium Carmustine Deferoxamine Mesylate Ifosfamide Busulphan Acamprosate Calcium Mesna Sodium 0155098-0000 Modafinil Omethoate Coumaphos Chlorpyriphos-Methyl Fenchlorphos Leptophos Profenofos Bromfenvinphos Tetrachlorvinphos Fensulfothion Isomalathion Tetraethyl Pyrophosphate Phorate Arsenic Trioxide Trichlorfon Fosfomycin Tromethamine L-690,330 Risedronate Sodium Clodronic acid disodium salt Tiludronate Disodium (N-Benzylthiocarbamoyl)-L-Cysteine, S- S7 Acetylcysteine DL-Thiorphan Actarit Aminohippuric Acid o-Iodohippuric Acid Aspartame Related Compound A H-Glu-Tyr-OH H-Tyr-Tyr-OH Aspartame Epibestatin HCl Nateglinide 4-P-PDOT Acetaminophen Acetanilide Phenacetin Benzocaine Butamben Methyl Anthranilate Exalamide Mexiletine HCl 4-(N-[3-Chlorophenyl]-Carbamoyloxy)-2-Butynyltrimethylammonium Chloride Barban PF-02543547-00 Felbamate Meprobamate Fenoxycarb Metaxalone Racecadotril Fluvoxamine Maleate Gabexate Mesylate Pentamidine Isethionate Baclofen Cetraxate HCl Gabapentin Trans-4-(Aminomethyl)-Cyclohexanecarboxylic Acid Aminocaproic Acid Aminolevulinic Acid HCl Vigabatrin Azelaic Acid Undecylenic Acid Chlorobutanol Hexylene Glycol Penicillamine S8 Dimercaprol Sorbitol AM-580 Bezafibrate Diatrizoic Acid Diatrizoic Acid Related compound A Iothalamic Acid Aceclofenac Diclofenac Sodium Iodipamide Ipodate Sodium Flufenamic Acid Niflumic Acid Chloramphenicol Chloramphenicol Palmitate Iohexol Iopamidol Metrizamide Efavirenz L-701,252 Flumequine Pazufloxacin Ochratoxin A L-689,560 Rebamipide PD-0167868-0000 Statil Balsalazide Olsalazine Disodium AG 957 Tranilast PD 098,059 ST638 Colchicine Trimethylcolchicinic Acid Minocycline HCl Oxytetracycline Novobiocin Carbidopa Levodopa Methyldopa Metyrosine Liothyronine S9 Aminosalicylic Acid Mesalamine m-Aminophenol Salicylamide Levonordefrin Metaraminol L-Bitartrate Pseudoephedrine HCl Tyrphostin 51 Tyrphostin A9 Tyrphostin AG 879 Capsazepine A-77636 HCl Fenoldopam Dihydrexidine HCl Norapomorphine HBr, R(-)- Nebivolol, hydrochloride Paroxetine 2-Methyl-5-Hydroxytryptamine Maleate BW 723C86 HCl Oxitriptan 6-Chloromelatonin Melatonin CP-099994-01 Primaquine Phosphate Tegaserod Maleate Atomoxetine HCl Nisoxetine HCl Fluoxetine HCl Bifemelane Methoctramine TetraHCl Propafenone HCl Maprotiline HCl Nortriptyline HCl Protriptyline HCl Acebutolol HCl Atenolol Carteolol HCl Formoterol Fumarate DiH2O UK-538348-40 Procaterol HCl Benserazide HCl Midodrine HCl SC-39566A S10 Capsaicin Dihydrocapsaicin Flecainide Acetate Rolipram Troxipide Anisomycin Carvedilol Isamoltane Hemifumarate Bopindolol Malonate Pindolol Propranolol HCl Betaxolol HCl Metoprolol Fumarate Oxprenolol HCl Levobunolol HCl Nadolol Penbutolol Sulfate CP-114271 BRL 37344 Sodium Fenoterol HBr UK-519218-02 Albuterol Terbutaline Sulfate Epinephrine L-Bitartrate Phenylephrine HCl Isoproterenol HCl Norepinephrine L-Bitartrate Clenbuterol HCl Tulobuterol HCl Suloctidil Deflazacort Docetaxel Paclitaxel Amphotericin B Nystatin Mepartricin A Aclarubicin HCl Azithromycin Clarithromycin Erythromycin Josamycin Dirithromycin Roxithromycin S11 Rapamycin Tacrolimus 7,8-Dihydroneopterin Zanamivir Hydrate Amikacin Arbekacin Sulfate Kanamycin Sulfate Paromomycin Sulfate Tobramycin Netilmicin Sulfate Sisomicin Sulfate Streptomycin Sulfate Miglitol Glucosamine HCl Voglibose 1,1-Dimethyl Biguanide HCl Altretamine Auramine O HCl Pinacidil Diphenylthiocarbazone Guanabenz Acetate M-Iodobenzylguanidine Hemisulfate Salt Phenformin HCl 5-(N-Ethyl-N-Isopropyl)-Amiloride Amiloride HCl Phenamil Methanesulfonate Anilazine Irsogladine Maleate Lamotrigine WY-14643 10, 11-Epoxy Carbamazepine Carbamazepine Oxcarbazepine 3,4,4'-Trichlorocarbanilide Diflubenzuron Guanfacine HCl Phenacemide Acetohydroxamic Acid Hydroxyurea Zileuton Ciclopirox Olamine 3-Amino-6-chloro-1-methyl-4-phenylcarbostyril Pirfenidone S12 Fluridon Amrinone Milrinone Niacinamide Pyrazinamide N-Methyl-Beta-Carboline-3-Carboxamide TJU103 Amlexanox Alloxazine Pteroic Acid Albendazole Parbendazole Mebendazole Cycloserine Isocarboxazid Leflunomide Isradipine NVP-ABE-171 5-Phenylhydantoin Phenytoin Pemoline 0119307-0015 PD-0136095-0002 Siguazodan Zardaverine CP-057915 Fluorouracil Carmofur Uracil Mustard Amobarbital Pentobarbital Secobarbital Mephobarbital Phenobarbital Primidone 5-Nitro-6,7-Dichloro-1,4-Dihydro-2,3-Quinoxalinedione Flutamide Acenocoumarol 5,5'-Dithiobis(2-Nitrobenzoic Acid) 3,5-Dinitrocatechol Ro 41-0960 Niclosamide Nifuroxazide S13 Nitrofurazone 1,1'-Trimethylenebis[4-(Hydroxyiminomethyl)Pyridinium Bromide Asoxime Chloride Pralidoxime Chloride 0151832-0042 NO-711 HCl Oxyphencyclimine HCl Furaltadone Furazolidone Nitrofurantoin Molsidomine Oxadixyl Etanidazole N-Benzyl-2-Nitro-1 H-Imidazole-1-Acetamide Ornidazole Secnidazole Oxamniquine Quipazine, 6-Nitro-, Maleate Amlodipine Maleate Salt Diethyl 1,4-Dihydro-2,6-Dimethyl-3,5-Pyridinedicarboxylate Felodipine Lacidipine Methyl 2-(Phenylthio)Ethyl 1,4-Dihydro-2,4,6-Trimethylpyridine-3,5- Dicarboxylate Nicardipine HCl Nifedipine Nisoldipine Nitrendipine Chlordiazepoxide HCl Flunitrazepam Clonazepam Nitrazepam Bromazepam Desalkylflurazepam Nordazepam 1-(2-Chlorophenyl)-N-Methyl-N-(1-Methylpropyl)-3-Isoquinolinecarboxamide
Recommended publications
  • Endothelin System and Therapeutic Application of Endothelin Receptor

    Endothelin System and Therapeutic Application of Endothelin Receptor

    xperim ACCESS Freely available online & E en OPEN l ta a l ic P in h l a C r m f o a c l a o n l o r g u y o J Journal of ISSN: 2161-1459 Clinical & Experimental Pharmacology Research Article Endothelin System and Therapeutic Application of Endothelin Receptor Antagonists Abebe Basazn Mekuria, Zemene Demelash Kifle*, Mohammedbrhan Abdelwuhab Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia ABSTRACT Endothelin is a 21 amino acid molecule endogenous potent vasoconstrictor peptide. Endothelin is synthesized in vascular endothelial and smooth muscle cells, as well as in neural, renal, pulmonic, and inflammatory cells. It acts through a seven transmembrane endothelin receptor A (ETA) and endothelin receptor B (ETB) receptors belongs to G protein-coupled rhodopsin-type receptor superfamily. This peptide involved in pathogenesis of cardiovascular disorder like (heart failure, arterial hypertension, myocardial infraction and atherosclerosis), renal failure, pulmonary arterial hypertension and it also involved in pathogenesis of cancer. Potentially endothelin receptor antagonist helps the treatment of the above disorder. Currently, there are a lot of trails both per-clinical and clinical on endothelin antagonist for various cardiovascular, pulmonary and cancer disorder. Some are approved by FAD for the treatment. These agents are including both selective and non-selective endothelin receptor antagonist (ETA/B). Currently, Bosentan, Ambrisentan, and Macitentan approved
  • Impaired Cellular Immunity in the Murine Neural Crest Conditional Deletion of Endothelin Receptor-B Model of Hirschsprung’S Disease

    Impaired Cellular Immunity in the Murine Neural Crest Conditional Deletion of Endothelin Receptor-B Model of Hirschsprung’S Disease

    RESEARCH ARTICLE Impaired Cellular Immunity in the Murine Neural Crest Conditional Deletion of Endothelin Receptor-B Model of Hirschsprung’s Disease Ankush Gosain1,2*, Amanda J. Barlow-Anacker1, Chris S. Erickson1, Joseph F. Pierre1, Aaron F. Heneghan1, Miles L. Epstein2, Kenneth A. Kudsk1,3 a11111 1 Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America, 2 Department of Neuroscience, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America, 3 Veteran Administration Surgical Service, William S. Middleton Memorial Veterans Hospital, Madison, United States of America * [email protected] OPEN ACCESS Citation: Gosain A, Barlow-Anacker AJ, Erickson Abstract CS, Pierre JF, Heneghan AF, Epstein ML, et al. (2015) Impaired Cellular Immunity in the Murine Hirschsprung’s disease (HSCR) is characterized by aganglionosis from failure of neural crest Neural Crest Conditional Deletion of Endothelin cell (NCC) migration to the distal hindgut. Up to 40% of HSCR patients suffer Hirschsprung’s- Receptor-B ’ Model of Hirschsprung s Disease. PLoS associated enterocolitis (HAEC), with an incidence that is unchanged from the pre-operative ONE 10(6): e0128822. doi:10.1371/journal. pone.0128822 to the post-operative state. Recent reports indicate that signaling pathways involved in NCC migration may also be involved in the development of secondary lymphoid organs. We hy- Academic Editor: Anatoly V. Grishin, Childrens Hospital Los Angeles, UNITED STATES pothesize that gastrointestinal (GI) mucosal immune defects occur in HSCR that may contrib- ute to enterocolitis. EdnrB was deleted from the neural crest (EdnrBNCC-/-) resulting in mutants Received: November 12, 2014 with defective NCC migration, distal colonic aganglionosis and the development of enterocoli- Accepted: May 1, 2015 tis.
  • Receptor-Mediated Dimerization of JAK2 FERM Domains Is Required for JAK2 Activation Ryan D Ferrao, Heidi JA Wallweber, Patrick J Lupardus*

    Receptor-Mediated Dimerization of JAK2 FERM Domains Is Required for JAK2 Activation Ryan D Ferrao, Heidi JA Wallweber, Patrick J Lupardus*

    RESEARCH ARTICLE Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation Ryan D Ferrao, Heidi JA Wallweber, Patrick J Lupardus* Department of Structural Biology, Genentech, Inc., South San Francisco, United States Abstract Cytokines and interferons initiate intracellular signaling via receptor dimerization and activation of Janus kinases (JAKs). How JAKs structurally respond to changes in receptor conformation induced by ligand binding is not known. Here, we present two crystal structures of the human JAK2 FERM and SH2 domains bound to Leptin receptor (LEPR) and Erythropoietin receptor (EPOR), which identify a novel dimeric conformation for JAK2. This 2:2 JAK2/receptor dimer, observed in both structures, identifies a previously uncharacterized receptor interaction essential to dimer formation that is mediated by a membrane-proximal peptide motif called the ‘switch’ region. Mutation of the receptor switch region disrupts STAT phosphorylation but does not affect JAK2 binding, indicating that receptor-mediated formation of the JAK2 FERM dimer is required for kinase activation. These data uncover the structural and molecular basis for how a cytokine-bound active receptor dimer brings together two JAK2 molecules to stimulate JAK2 kinase activity. DOI: https://doi.org/10.7554/eLife.38089.001 Introduction Janus kinases (JAKs) are a family of multi-domain non-receptor tyrosine kinases responsible for pleio- tropic regulatory effects on growth, development, immune and hematopoietic signaling (Leonard and O’Shea, 1998). The JAK family consists of four conserved members, including JAK1, *For correspondence: [email protected] JAK2, JAK3, and TYK2, which are differentially activated in response to cytokine and interferon stim- ulation. JAKs are constitutively bound to the intracellular domains of their cognate cytokine signaling Competing interest: See receptors, and are activated after cytokine-mediated dimerization or rearrangement of these recep- page 18 tors establishes a productive receptor signaling complex (Haan et al., 2006).
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
  • Specifications of Approved Drug Compound Library

    Specifications of Approved Drug Compound Library

    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
  • AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
  • Histamine Receptors

    Histamine Receptors

    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
  • Receptor Antagonist (H RA) Shortages | May 25, 2020 2 2 2 GERD4,5 • Take This Opportunity to Determine If Continued Treatment Is Necessary

    Receptor Antagonist (H RA) Shortages | May 25, 2020 2 2 2 GERD4,5 • Take This Opportunity to Determine If Continued Treatment Is Necessary

    H2-receptor antagonist (H2RA) Shortages Background . 2 H2RA Alternatives . 2 Therapeutic Alternatives . 2 Adults . 2 GERD . 3 PUD . 3 Pediatrics . 3 GERD . 3 PUD . 4 Tables Table 1: Health Canada–Approved Indications of H2RAs . 2 Table 2: Oral Adult Doses of H2RAs and PPIs for GERD . 4 Table 3: Oral Adult Doses of H2RAs and PPIs for PUD . 5 Table 4: Oral Pediatric Doses of H2RAs and PPIs for GERD . 6 Table 5: Oral Pediatric Doses of H2RAs and PPIs for PUD . 7 References . 8 H2-receptor antagonist (H2RA) Shortages | May 25, 2020 1 H2-receptor antagonist (H2RA) Shortages BACKGROUND Health Canada recalls1 and manufacturer supply disruptions may be causing shortages of commonly used acid-reducing medications called histamine H2-receptor antagonists (H2RAs) . H2RAs include cimetidine, famotidine, nizatidine and ranitidine . 2 There are several Health Canada–approved indications of H2RAs (see Table 1); this document addresses the most common: gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) . 2 TABLE 1: HEALTH CANADA–APPROVED INDICATIONS OF H2RAs H -Receptor Antagonists (H RAs) Health Canada–Approved Indications 2 2 Cimetidine Famotidine Nizatidine Ranitidine Duodenal ulcer, treatment ü ü ü ü Duodenal ulcer, prophylaxis — ü ü ü Benign gastric ulcer, treatment ü ü ü ü Gastric ulcer, prophylaxis — — — ü GERD, treatment ü ü ü ü GERD, maintenance of remission — ü — — Gastric hypersecretion,* treatment ü ü — ü Self-medication of acid indigestion, treatment and prophylaxis — ü† — ü† Acid aspiration syndrome, prophylaxis — — — ü Hemorrhage from stress ulceration or recurrent bleeding, — — — ü prophylaxis ü = Health Canada–approved indication; GERD = gastroesophageal reflux disease *For example, Zollinger-Ellison syndrome .
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E

    A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E

    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
  • In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs As Inverse H1 Receptor Agonists

    In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs As Inverse H1 Receptor Agonists

    0022-3565/07/3221-172–179$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 322, No. 1 Copyright © 2007 by The American Society for Pharmacology and Experimental Therapeutics 118869/3215703 JPET 322:172–179, 2007 Printed in U.S.A. In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists R. A. Bakker,1 M. W. Nicholas,2 T. T. Smith, E. S. Burstein, U. Hacksell, H. Timmerman, R. Leurs, M. R. Brann, and D. M. Weiner Department of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (R.A.B., H.T., R.L.); ACADIA Pharmaceuticals Inc., San Diego, California (R.A.B., M.W.N., T.T.S., E.S.B., U.H., M.R.B., D.M.W.); and Departments of Pharmacology (M.R.B.), Neurosciences (D.M.W.), and Psychiatry (D.M.W.), University of California, San Diego, California Received January 2, 2007; accepted March 30, 2007 Downloaded from ABSTRACT The human histamine H1 receptor (H1R) is a prototypical G on this screen, we have reported on the identification of 8R- protein-coupled receptor and an important, well characterized lisuride as a potent stereospecific partial H1R agonist (Mol target for the development of antagonists to treat allergic con- Pharmacol 65:538–549, 2004). In contrast, herein we report on jpet.aspetjournals.org ditions. Many neuropsychiatric drugs are also known to po- a large number of varied clinical and chemical classes of drugs tently antagonize this receptor, underlying aspects of their side that are active in the central nervous system that display potent effect profiles.
  • Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes

    Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes

    Tohoku J. Exp. Med., 2011,Differential 223, 161-176 Gene Expression in OPCs, Oligodendrocytes and Type II Astrocytes 161 Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes Jian-Guo Hu,1,2,* Yan-Xia Wang,3,* Jian-Sheng Zhou,2 Chang-Jie Chen,4 Feng-Chao Wang,1 Xing-Wu Li1 and He-Zuo Lü1,2 1Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Bengbu, P.R. China 2Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical College, Bengbu, P.R. China 3Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China 4Department of Laboratory Medicine, Bengbu Medical College, Bengbu, P.R. China Oligodendrocyte precursor cells (OPCs) are bipotential progenitor cells that can differentiate into myelin-forming oligodendrocytes or functionally undetermined type II astrocytes. Transplantation of OPCs is an attractive therapy for demyelinating diseases. However, due to their bipotential differentiation potential, the majority of OPCs differentiate into astrocytes at transplanted sites. It is therefore important to understand the molecular mechanisms that regulate the transition from OPCs to oligodendrocytes or astrocytes. In this study, we isolated OPCs from the spinal cords of rat embryos (16 days old) and induced them to differentiate into oligodendrocytes or type II astrocytes in the absence or presence of 10% fetal bovine serum, respectively. RNAs were extracted from each cell population and hybridized to GeneChip with 28,700 rat genes. Using the criterion of fold change > 4 in the expression level, we identified 83 genes that were up-regulated and 89 genes that were down-regulated in oligodendrocytes, and 92 genes that were up-regulated and 86 that were down-regulated in type II astrocytes compared with OPCs.